ChiCTR2000030429 版本V1.0 版本创建时间2020/05/25 11:42:40 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000030429 

最近更新日期:

Date of Last Refreshed on:

2020-03-01 21:59:17 

注册时间:

Date of Registration:

2020-03-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

李琼珍医师:请尽快上传伦理审批文件并填写伦理审批日期。 右美托咪定联合舒芬太尼和地佐辛增加胸腔镜术后女性患者满意度

Public title:

Effect of dexmedetomidine combined with sufentanil and dizosin on increasing the satisfaction of female patients after thoracoscopy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

右美托咪定联合舒芬太尼和地佐辛增加胸腔镜术后女性患者满意度

Scientific title:

Effect of dexmedetomidine combined with sufentanil and dizosin on increasing the satisfaction of female patients after thoracoscopy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李琼珍 

研究负责人:

吴镜湘 

Applicant:

Qiongzhen Li 

Study leader:

Jingxiang Wu 

申请注册联系人电话:

Applicant telephone:

+86 18917129132

研究负责人电话:

Study leader's telephone:

+86 18019370636

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

475166534@qq.com

研究负责人电子邮件:

Study leader's E-mail:

Wu_jingxiang@shchest.org

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市徐汇区淮海西路241号

研究负责人通讯地址:

上海市徐汇区淮海西路241号

Applicant address:

241 Huaihai Road West, Xuhui District, Shanghai, China

Study leader's address:

241 Huaihai Road West, Xuhui District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海市胸科医院麻醉科

Applicant's institution:

Department of Anesthesiology, ShangHai Chest Hospital

研究负责人所在单位:

上海市胸科医院麻醉科

Affiliation of the Leader:

Department of Anesthesiology, ShangHai Chest Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KS1865

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

上海交通大学附属上海市胸科医院伦理委员会

Name of the ethic committee:

The Institutional Review Board of Shanghai Chest Hospital Affiliated to Shanghai Jiaotong University

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

徐美英

Contact Name of the ethic committee:

Meiying Xu

伦理委员会联系地址:

上海市徐汇区淮海西路241号

Contact Address of the ethic committee:

241 Huaihai Road West, Xuhui District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市胸科医院

Primary sponsor:

ShangHai Chest Hospital

研究实施负责(组长)单位地址:

上海市徐汇区淮海西路241号

Primary sponsor's address:

241 Huaihai Road West, Xuhui District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市胸科医院

具体地址:

徐汇区淮海西路241号

Institution
hospital:

ShangHai Chest Hospital

Address:

241 Huaihai Road West, Xuhui District

经费或物资来源:

上海市胸科医院

Source(s) of funding:

ShangHai Chest Hospital

Target disease:

thoracic tumor

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

术后疼痛及恶心呕吐一直是尚未良好解决的难题,发生最多的是女性患者,发生率高达60%,尤其是对于胸科手术。本研究拟在评估右美托咪定联合舒芬太尼和地佐辛用于静脉自控镇痛泵对女性患者胸腔镜术后满意度的影响。  

Objectives of Study:

Postoperative pain and PONV are unsolved problems and the incidence rate is as high as 60%, especially for female patients after thoracoscopic. The purpose of this study is to evaluate the effect of dexmedetomidine combined with sufentanil and dezocine on the satisfaction of female patients after thoracoscopy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 30-60岁女性患者;
2. ASAI 或 II;
3. 择期行胸腔镜肺叶切除术需术后48h静脉镇痛。

Inclusion criteria

1. Aged between 30 and 60 years;
2. Physical status I or II according to the American Society of Anesthesiologists;
3. Undergo Three trocars video-assisted thoracoscopic surgery,and received 48 h patient-controlled intravenous analgesia (PCIA) after surgery.

排除标准:

1. 精神类药物和酗酒史;
2. 心血管和肝肾疾病;
3. 认知障碍;
4. 怀孕或哺乳期。

Exclusion criteria:

1. Use of psychiatric medications and alcohol abuse;
2. With a history of Cardiovascular and liver and kidney disease;
3. Cognitive impairment;
4. Pregnant or lactating.

研究实施时间:

Study execute time:

From 2020-02-24 00:00:00 To 2020-04-02 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-02-24 00:00:00 To 2020-02-28 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

76

Group:

control group

Sample size:

干预措施:

舒芬太尼和地佐辛

干预措施代码:

Intervention:

sufentanil and dezocine

Intervention code:

组别:

试验组

样本量:

76

Group:

experimental group

Sample size:

干预措施:

右美托咪定联合舒芬太尼和地佐辛

干预措施代码:

Intervention:

dexmedetomidine combined with sufentanil and dezocine

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

上海市胸科医院 

单位级别:

三甲 

Institution
hospital:

ShangHai Chest Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

满意度

指标类型:

主要指标

Outcome:

satisfaction

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后恶心呕吐

指标类型:

次要指标

Outcome:

PONV

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视觉模拟评分

指标类型:

次要指标

Outcome:

VAS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

镇静评分

指标类型:

次要指标

Outcome:

Ramsay

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

麻醉护士采用投掷硬币的方法

Randomization Procedure (please state who generates the random number sequence and by what method):

toss coin by Anesthesia nurse

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台ResMan, http://www.medresman.org.cn。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan, www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF and Electronic Data

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-03-01 21:59:17